Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
A phase 1/2 trial of AZD4512 in acute lymphoblastic leukaemia, run by AstraZeneca, now recruiting.
Overview
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia is a phase 1/2 interventional study registered as NCT07109219 by AstraZeneca, with 83 participants planned, started 2025-11-12 and due to reach its primary completion in 2028-04-28. Interventions recorded: AZD4512 monotherapy.
Similar pages
not linked directly; found by shared links- TrialAZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Shares AstraZeneca, Acute lymphoblastic leukaemia and the tag pipeline.
- TrialStudy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Shares AstraZeneca, Acute lymphoblastic leukaemia and the tag pipeline.
- TrialClinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialA Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialCAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialStudy of YK012 in B-cell Acute Lymphoblastic Leukemia
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialStudy of AZD0754 in Participants With Metastatic Prostate Cancer
Shares AstraZeneca and the tag pipeline.
- TrialFirst-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer
Shares AstraZeneca and the tag pipeline.